Aurora Spine Corp (TSE:ASG)
:ASG
Top Page
Aurora Spine
(ASG)
Select Model
Select Model
Rating:46Neutral
Price Target:
C$0.29
▲(3.21% Upside)
Action:ReiteratedDate:12/19/25
Aurora Spine's overall stock score is primarily impacted by its financial performance challenges, including negative profitability and cash flow issues. Technical analysis shows a neutral trend, while valuation metrics are weak due to negative earnings and lack of dividends.
Positive Factors
Consistent revenue growth
Sustained revenue growth indicates expanding product adoption and market traction for Aurora Spine's implants and tools. Over the next 2–6 months this trend supports scale benefits, helps justify continued investment in R&D and commercialization, and underpins longer-term revenue stability.
Negative Factors
Negative profitability
Persistent negative net income and EBIT margins indicate operational inefficiencies or high fixed costs relative to current sales. Over months this limits retained earnings, reduces ability to self-fund growth, and requires either improved margins or external capital for sustained commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent revenue growth
Sustained revenue growth indicates expanding product adoption and market traction for Aurora Spine's implants and tools. Over the next 2–6 months this trend supports scale benefits, helps justify continued investment in R&D and commercialization, and underpins longer-term revenue stability.
Read all positive factors
Aurora Spine (ASG) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$21.31M
Dividend YieldN/A
Average Volume (3M)30.19K
Price to Earnings (P/E)―
Beta (1Y)0.28
Revenue Growth9.71%
EPS Growth-118.02%
CountryCA
Employees13
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding78,054,950
10 Day Avg. Volume38,837
30 Day Avg. Volume30,190
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)4.78
Price to Sales (P/S)1.20
P/FCF Ratio78.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Aurora Spine Business Overview & Revenue Model
Company Description
Aurora Spine (ASG) is a medical device company focused on developing innovative spinal implants and surgical solutions. The company operates in the orthopedic and spinal surgery sectors, providing a range of products that include interbody fusion ...
How the Company Makes Money
Aurora Spine generates revenue primarily through the sale of its spinal implants and surgical instruments to hospitals, surgical centers, and orthopedic surgeons. The company’s revenue model is based on direct sales and distribution agreements wit...
Aurora Spine Earnings Call Summary
Earnings Call Date:Apr 29, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:May 04, 2026
Earnings Call Sentiment Neutral
The earnings call highlights significant revenue growth, product success, and gross margin improvements. However, these positives are tempered by increased operating expenses, a fourth-quarter EBITDAC decline, and a sustained net loss. While Aurora's product portfolio shows promise, financial challenges remain.Positive Updates
Revenue Growth
Aurora Spine reported a 21% increase in revenue for fiscal year 2024, reaching $17.56 million compared to $14.52 million in 2023.
Negative Updates
Increased Operating Expenses
Operating expenses increased to $11.438 million for fiscal year 2024, up from $9.89 million in 2023, due to higher training and staff costs.
Read all updates
Q4-2024 Updates
Positive
Negative
Revenue Growth
Aurora Spine reported a 21% increase in revenue for fiscal year 2024, reaching $17.56 million compared to $14.52 million in 2023.
Read all positive updates
Company Guidance
During the Aurora Spine Fourth Quarter and Fiscal Year 2024 Results Conference Call, a comprehensive financial and operational overview was provided. The company reported a 21% increase in revenue for 2024, reaching $17.56 million compared to $14.52 million in 2023. Notably, the SiLO-TFX system saw a remarkable 135% increase in revenue, contributing significantly to this growth. The ZIP series, particularly ZIP-51, experienced a 69% increase in sales. Gross margins improved to 60.5% for the fiscal year, up from 56.5% in 2023, attributed to the focus on proprietary products and better pricing strategies. Operating expenses rose to $11.438 million, driven by increased sales personnel and training costs. EBITDAC for 2024 turned positive at $0.28 million, a significant improvement from a negative $0.31 million in 2023. Net loss for the year reduced to $1.003 million from $1.68 million in 2023. The company ended the quarter with $0.826 million in cash, and management expressed confidence in their capital structure to meet budgetary needs, focusing on profitability and continued growth with new product launches and clinical studies.Aurora Spine Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
50
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 18.05M | 17.56M | 14.52M | 14.88M | 10.54M | 8.65M |
| Gross Profit | 10.78M | 10.63M | 8.21M | 7.81M | 4.83M | 3.47M |
| EBITDA | -121.65K | 179.90K | -446.20K | -469.27K | -1.55M | -573.86K |
| Net Income | -1.34M | -1.00M | -1.68M | -1.50M | -2.36M | -232.09K |
Balance Sheet | ||||||
| Total Assets | 11.69M | 11.67M | 11.99M | 10.12M | 10.56M | 7.16M |
| Cash, Cash Equivalents and Short-Term Investments | 926.33K | 775.62K | 766.83K | 423.40K | 3.17M | 1.71M |
| Total Debt | 3.59M | 3.67M | 3.65M | 2.97M | 2.55M | 2.34M |
| Total Liabilities | 7.86M | 7.28M | 6.69M | 5.81M | 4.99M | 3.87M |
| Stockholders Equity | 3.83M | 4.40M | 5.30M | 4.32M | 5.57M | 3.28M |
Cash Flow | ||||||
| Free Cash Flow | -59.98K | 266.47K | -1.41M | -2.43M | -2.85M | -245.07K |
| Operating Cash Flow | 673.38K | 904.33K | -935.06K | -1.56M | -2.13M | 309.57K |
| Investing Cash Flow | -486.99K | -484.32K | -479.13K | -873.21K | -720.61K | -554.64K |
| Financing Cash Flow | -369.08K | -361.22K | 1.76M | -318.15K | 4.31M | 1.51M |
Aurora Spine Technical Analysis
Negative
0.28
Price Trends
0.28
Negative
0.28
Negative
0.29
Negative
Market Momentum
>-0.01
Positive
47.22
Neutral
46.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ASG, the sentiment is Negative. The current price of 0.28 is above the 20-day moving average (MA) of 0.28, below the 50-day MA of 0.28, and below the 200-day MA of 0.29, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 47.22 is Neutral, neither overbought nor oversold. The STOCH value of 46.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ASG.
Aurora Spine Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$21.58M | -5.28 | 106.68% | ― | 28.59% | 23.46% | |
46 Neutral | C$21.31M | -29.60 | -31.12% | ― | 9.71% | -118.02% | |
46 Neutral | C$69.41M | -11.76 | -269.41% | ― | 1.46% | 6.91% | |
42 Neutral | C$41.62M | -1.50 | -220.14% | ― | 209.29% | 35.38% |
* Healthcare Sector Average
TSE:ASG
Aurora Spine
0.27
-0.04
-11.94%
TSE:PINK
Perimeter Medical Imaging AI
0.33
-0.05
-14.29%
TSE:TLT
Theralase Technologies
0.27
0.10
58.82%
TSE:VPT
VentriPoint Diagnostics
0.12
>-0.01
-8.00%
Aurora Spine Corporate Events
Business Operations and StrategyProduct-Related Announcements
Aurora Spine Bolsters IP Portfolio With Two New U.S. Patents
Positive
Jan 8, 2026
Aurora Spine has secured two new U.S. patents that broaden protection for its core implant platforms and deepen its technological differentiation in minimally invasive spine surgery. One patent, the tenth for the company’s flagship ZIP impla...
Financial DisclosuresProduct-Related Announcements
Aurora Spine Reports Record Q3 2025 Results Amid Product Launches
Positive
Nov 18, 2025
Aurora Spine Corporation announced record financial results for the third quarter of 2025, marking a significant period of transition with the launch of two new product platforms, DEXA-L and Hydra ARO. Despite a slight decrease in total revenues c...
Business Operations and StrategyProduct-Related Announcements
Aurora Spine to Showcase Innovations at NASS 2025
Positive
Nov 13, 2025
Aurora Spine Corporation announced its participation in the 2025 North American Spine Society Annual Meeting, where it will showcase its latest innovations at Booth #1622. The company will feature its newly launched Hydra Facet Fusion System and t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.